BioCentury
ARTICLE | Company News

Seattle Genetics and BMS combining Adcetris and Opdivo in Ph III trial

June 16, 2017 8:29 PM UTC

Seattle Genetics Inc. (NASDAQ:SGEN) and Bristol-Myers Squibb Co. (NYSE:BMY) partnered to evaluate Seattle's Adcetris brentuximab with or without PD-1 inhibitor Opdivo nivolumab to treat patients with relapsed, refractory or transplant-ineligible advanced classical Hodgkin's lymphoma (CHL). The partners plan to start the international, open-label Phase III trial by mid-2017. ...